Joanna W Etra1,2, Giorgio Raimondi1, Gerald Brandacher1. 1. Department of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory. 2. Department of General Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Abstract
PURPOSE OF REVIEW: For patients with devastating injuries in whom standard reconstruction is not an option, vascularized composite allotransplantation (VCA) has become a viable means of restoring form and function. However, immunological rejection continues to be a problem in VCA and has not yet been fully characterized. As the field is relatively new, much of the data on rejection and immunosuppression have been extrapolated from that of solid organ transplantation. In this review, we cover the basic mechanisms of rejection as they relate specifically to VCA with analysis of recent literature and future directions. RECENT FINDINGS: Recent clinical studies have supported previously postulated T-cell-mediated mechanism of acute rejection and have also made strides in differentiating rejection from inflammation from other skin conditions and with different treatment regimens. Antibody-mediated rejection has been described in recent cases as well as treatment of presensitized patients receiving VCAs. With more long-term grafts, chronic changes, including vasculopathy, are being reported. SUMMARY: Clinically observed types of rejection in VCA include mainly cell-mediated, antibody-mediated and chronic rejection. Advances in diagnosis and treatment of rejection have been made, but there is still much to be learned about VCA-specific rejection.
PURPOSE OF REVIEW: For patients with devastating injuries in whom standard reconstruction is not an option, vascularized composite allotransplantation (VCA) has become a viable means of restoring form and function. However, immunological rejection continues to be a problem in VCA and has not yet been fully characterized. As the field is relatively new, much of the data on rejection and immunosuppression have been extrapolated from that of solid organ transplantation. In this review, we cover the basic mechanisms of rejection as they relate specifically to VCA with analysis of recent literature and future directions. RECENT FINDINGS: Recent clinical studies have supported previously postulated T-cell-mediated mechanism of acute rejection and have also made strides in differentiating rejection from inflammation from other skin conditions and with different treatment regimens. Antibody-mediated rejection has been described in recent cases as well as treatment of presensitized patients receiving VCAs. With more long-term grafts, chronic changes, including vasculopathy, are being reported. SUMMARY: Clinically observed types of rejection in VCA include mainly cell-mediated, antibody-mediated and chronic rejection. Advances in diagnosis and treatment of rejection have been made, but there is still much to be learned about VCA-specific rejection.
Authors: Laura C Burlage; Shannon N Tessier; Joanna W Etra; Korkut Uygun; Gerald Brandacher Journal: Curr Opin Organ Transplant Date: 2018-10 Impact factor: 2.640
Authors: Thet Su Win; William J Crisler; Beatrice Dyring-Andersen; Rachel Lopdrup; Jessica E Teague; Qian Zhan; Victor Barrera; Shannan Ho Sui; Sotirios Tasigiorgos; Naoka Murakami; Anil Chandraker; Stefan G Tullius; Bohdan Pomahac; Leonardo V Riella; Rachael A Clark Journal: J Clin Invest Date: 2021-04-15 Impact factor: 14.808
Authors: Flemming Puscz; Mehran Dadras; Alexander Dermietzel; Frank Jacobsen; Marcus Lehnhardt; Björn Behr; Tobias Hirsch; Maximilian Kueckelhaus Journal: PLoS One Date: 2020-06-26 Impact factor: 3.240
Authors: Joanna W Etra; Michael J Grzelak; Samuel A J Fidder; Keli Kolegraff; Steven Bonawitz; Jaimie Shores; Byoungchol Oh; Damon S Cooney; Sarah E Beck; Gerald Brandacher Journal: Transplantation Date: 2019-07 Impact factor: 4.939